GlobeNewswire: Voyager Therapeutics, Inc. Contains the last 10 of 213 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:27:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852716/0/en/Voyager-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-03-26T20:01:00Z<![CDATA[LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby Ferguson, M.D., Ph.D. that, among other things, provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on March 25, 2024, and the restricted stock unit award is scheduled to become effective on April 1, 2024.]]>https://www.globenewswire.com/news-release/2024/03/13/2845288/0/en/Voyager-Therapeutics-Announces-Appointment-of-Toby-Ferguson-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer2024-03-13T11:00:00Z<![CDATA[LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc.]]>https://www.globenewswire.com/news-release/2024/02/28/2837391/0/en/Voyager-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results2024-02-28T21:01:00Z<![CDATA[- Company had approximately $431 million in pro-forma cash as of December 31, 2023, adjusted for $100 million consideration from Novartis agreements and $100 million public offering -]]>https://www.globenewswire.com/news-release/2024/02/26/2834995/0/en/Voyager-Therapeutics-Announces-Selection-of-Gene-Therapy-Development-Candidate-for-Friedreich-s-Ataxia-in-Collaboration-with-Neurocrine-Biosciences-Triggering-Milestone-Payment.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment2024-02-26T12:00:00Z<![CDATA[LEXINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the Friedreich’s ataxia (FA) program. The candidate combines a frataxin (FXN) gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform. The companies expect the program to advance into first-in-human clinical trials in 2025.]]>https://www.globenewswire.com/news-release/2024/02/21/2832613/0/en/Voyager-Therapeutics-Announces-Fourth-Quarter-2023-Conference-Call-and-Webcast.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast2024-02-21T12:00:00Z<![CDATA[LEXINGTON, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2023 financial and operating results after market close on Wednesday, February 28, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.]]>https://www.globenewswire.com/news-release/2024/02/20/2831662/0/en/Voyager-Therapeutics-Reports-Robust-Preclinical-Activity-in-Tau-Silencing-Gene-Therapy-Program-for-Alzheimer-s-Disease-and-Advances-Program-into-Late-Research.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research2024-02-20T12:00:00Z<![CDATA[- Additional new data demonstrate VY-TAU01, Voyager’s lead antibody targeting pathological tau, was well-tolerated and demonstrated favorable pharmacokinetics in non-human primates (NHPs) -]]>https://www.globenewswire.com/news-release/2024/02/07/2825060/0/en/Voyager-Therapeutics-to-Present-at-the-Oppenheimer-Annual-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences Conference2024-02-07T12:00:00Z<![CDATA[LEXINGTON, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Financial Officer Peter Pfreundschuh will present at the Oppenheimer Life Sciences Conference on February 14, 2024, at 11:20 a.m. ET.]]>https://www.globenewswire.com/news-release/2024/01/05/2804439/0/en/Voyager-Therapeutics-Announces-Pricing-of-Public-Offering.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Announces Pricing of Public Offering2024-01-05T03:45:43Z<![CDATA[LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who so choose in lieu of common stock, pre-funded warrants to purchase an aggregate of 3,333,333 shares of common stock at a public offering price of $8.999 per pre-funded warrant, for aggregate gross proceeds of approximately $100 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The purchase price per pre-funded warrant represents the per share public offering price for the common stock, minus the $0.001 per share exercise price of each pre-funded warrant. All of the securities in the offering are being sold by the Company. The offering is expected to close on or about January 9, 2024, subject to the satisfaction of customary closing conditions. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,666,665 shares of its common stock at the public offering price, less underwriting discounts and commissions.]]>https://www.globenewswire.com/news-release/2024/01/04/2804338/0/en/Voyager-Therapeutics-Announces-Proposed-Public-Offering.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics Announces Proposed Public Offering2024-01-04T21:14:15Z<![CDATA[LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof). All of the securities in the proposed offering are to be sold by the Company. In addition, the Company expects to grant the underwriters of the offering a 30-day option to purchase up to an additional $15 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2024/01/03/2803156/0/en/Voyager-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=27673Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T12:00:00Z<![CDATA[LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024, at 9:45 a.m. PT (12:45 p.m. ET).]]>